Immuneel Therapeutics launches affordable CAR-T therapy Qartemi for B-cell Non-Hodgkin Lymphoma, aiming to revolutionize ...

Yescarta continued to demonstrate durable responses after a median follow-up of more than five years in patients with R/R indolent non-Hodgkin lymphoma.

LONDON - Autolus Therapeutics plc (NASDAQ:AUTL), a biopharmaceutical company specializing in T cell therapies for cancer, has announced its participation in the upcoming 2025 Tandem Meetings | ...

Shaw, has introduced Qartemi, India's second CAR-T cell therapy, to treat B-cell Non-Hodgkin Lymphoma. This therapy is priced ...

The therapy can cost anywhere between $350,000 and $700,000 globally. While Immuneel has brought it down to about ₹51 lakh to ...

Immuneel Therapeutics introduces Qartemi, India's first personalised CAR T-cell therapy for B-NHL, offering affordable ...

T-cell therapy, originally developed for haematological malignancies, has recently emerged as a promising therapy for ...

India faces a rising burden of blood cancers, with around 120,000 new cases and over 70,000 deaths annually from leukemia, ...

Request To Download Free Sample of This Strategic Report @ The report provides in-depth analysis and insights regarding the current global market scenario, latest trends and drivers into global CAR T ...

India’s first global CAR T-cell therapy for adult B-cell Non-Hodgkin Lymphoma (B-NHL), a kind of blood cancer that affects ...

Patent-filing research conducted by law firm Withers & Rogers suggests that CAR T-cell therapy capability has reached a pivotal point on route to market, and first-line use of these promising ...

In a significant step forward for India’s cancer treatment, Immuneel Therapeutics, a leading cell and gene therapy statrtup ...